Literature DB >> 33306174

Taccalonolide Microtubule Stabilizers.

Samantha S Yee1, Lin Du2, April L Risinger3.   

Abstract

Microtubule stabilizers are a mainstay in the treatment of many solid cancers and continue to find utility in combination therapy with molecularly targeted anticancer agents and immunotherapeutics. However, innate and acquired resistance to microtubule stabilizers can limit their clinical efficacy. The taccalonolides are a unique class of microtubule stabilizers isolated from plants of Tacca that circumvent clinically relevant mechanisms of drug resistance. Although initial reports suggested that the microtubule-stabilizing activity of the taccalonolides was independent of direct tubulin binding, additional studies have identified that potent C-22, C-23 epoxidized taccalonolides covalently bind the Aspartate 226 residue of β-tubulin and that this interaction is critical for their microtubule-stabilizing activity. The taccalonolides have distinct properties as compared to other microtubule stabilizers with regard to their biochemical effects on tubulin structure and dynamics that promote distinct cellular phenotypes. Some taccalonolides have demonstrated in vivo antitumor efficacy in drug-resistant tumor models with exquisite potency and long-lasting antitumor efficacy as a result of their irreversible target engagement. The recent identification of a site on the taccalonolide scaffold that is amenable to modification has provided evidence of the specificity of the taccalonolide-tubulin interaction. This also affords an opportunity to further optimize the targeted delivery of the taccalonolides to further improve their anticancer efficacy and potential for clinical development.

Entities:  

Keywords:  Antitumor natural product; Microtubule stabilizer; Microtubule-targeted agent; Taccalonolide

Year:  2020        PMID: 33306174     DOI: 10.1007/978-3-030-52966-6_3

Source DB:  PubMed          Journal:  Prog Chem Org Nat Prod        ISSN: 0071-7886


  30 in total

1.  Taccalonolides: a microtubule stabilizer poses a new puzzle with old pieces.

Authors:  Dan L Sackett; Tito Fojo
Journal:  Cell Cycle       Date:  2011-10-01       Impact factor: 4.534

2.  Five taccalonolides from Tacca plantaginea.

Authors:  Z L Chen; J H Shen; Y S Gao; M Wichtl
Journal:  Planta Med       Date:  1997-02       Impact factor: 3.352

3.  Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization.

Authors:  P Giannakakou; D L Sackett; Y K Kang; Z Zhan; J T Buters; T Fojo; M S Poruchynsky
Journal:  J Biol Chem       Date:  1997-07-04       Impact factor: 5.157

4.  A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells.

Authors:  P Giannakakou; R Gussio; E Nogales; K H Downing; D Zaharevitz; B Bollbuck; G Poy; D Sackett; K C Nicolaou; T Fojo
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

5.  Identification and biological activities of new taccalonolide microtubule stabilizers.

Authors:  Jiangnan Peng; April L Risinger; Gary A Fest; Evelyn M Jackson; Gregory Helms; Lisa A Polin; Susan L Mooberry
Journal:  J Med Chem       Date:  2011-08-11       Impact factor: 7.446

6.  Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the paclitaxel site predicts cytotoxicity.

Authors:  Rubén M Buey; Isabel Barasoain; Evelyn Jackson; Arndt Meyer; Paraskevi Giannakakou; Ian Paterson; Susan Mooberry; José M Andreu; J Fernando Díaz
Journal:  Chem Biol       Date:  2005-12

7.  MDA-MB-435 cells are derived from M14 melanoma cells--a loss for breast cancer, but a boon for melanoma research.

Authors:  James M Rae; Chad J Creighton; Jeanne M Meck; Bassem R Haddad; Michael D Johnson
Journal:  Breast Cancer Res Treat       Date:  2006-09-27       Impact factor: 4.872

8.  Cellular studies reveal mechanistic differences between taccalonolide A and paclitaxel.

Authors:  April L Risinger; Susan L Mooberry
Journal:  Cell Cycle       Date:  2011-07-01       Impact factor: 4.534

9.  Taccalonolides E and A: Plant-derived steroids with microtubule-stabilizing activity.

Authors:  Tina L Tinley; Deborah A Randall-Hlubek; Rachel M Leal; Evelyn M Jackson; James W Cessac; James C Quada; Thomas K Hemscheidt; Susan L Mooberry
Journal:  Cancer Res       Date:  2003-06-15       Impact factor: 12.701

10.  The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms.

Authors:  April L Risinger; Evelyn M Jackson; Lisa A Polin; Gregory L Helms; Desiree A LeBoeuf; Patrick A Joe; Elizabeth Hopper-Borge; Richard F Ludueña; Gary D Kruh; Susan L Mooberry
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

View more
  3 in total

1.  Design, Synthesis, and Biological Evaluation of 5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidines as Microtubule Targeting Agents.

Authors:  Farhana Islam; Arpit Doshi; Andrew J Robles; Tasdique M Quadery; Xin Zhang; Xilin Zhou; Ernest Hamel; Susan L Mooberry; Aleem Gangjee
Journal:  Molecules       Date:  2022-01-05       Impact factor: 4.411

Review 2.  Antitumor Profile of Carbon-Bridged Steroids (CBS) and Triterpenoids.

Authors:  Valery M Dembitsky; Tatyana A Gloriozova; Vladimir V Poroikov
Journal:  Mar Drugs       Date:  2021-06-03       Impact factor: 5.118

3.  Taccalonolide C-6 Analogues, Including Paclitaxel Hybrids, Demonstrate Improved Microtubule Polymerizing Activities.

Authors:  April L Risinger; Shayne D Hastings; Lin Du
Journal:  J Nat Prod       Date:  2021-06-10       Impact factor: 4.803

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.